直接口服抗凝药的胃肠道安全性:一项大型人群研究
该回顾性倾向匹配研究利用OptumLabs数据仓库的行政索赔数据,构建三组非瓣膜性房颤患者队列,分别比较达比加群、利伐沙班和阿哌沙班的胃肠道出血风险。结果显示阿哌沙班的胃肠道安全性最佳,利伐沙班最差;所有DOAC在75岁及以上患者中出血率均升高。
要点
- 利伐沙班的胃肠道出血风险高于达比加群(HR 1.20,95%CI 1.00-1.45)。
- 阿哌沙班的胃肠道出血风险低于达比加群(HR 0.39,95%CI 0.27-0.58,P<.001)和利伐沙班(HR 0.33,95%CI 0.22-0.49,P<.001)。
- 在75岁及以上高龄患者中,阿哌沙班的胃肠道出血风险仍低于达比加群(HR 0.45)和利伐沙班(HR 0.39)。
核心结论
- 在服用DOAC的患者中,阿哌沙班具有最有利的胃肠道安全性特征,利伐沙班最不利;所有年龄组中阿哌沙班的胃肠道安全性均最佳。
- 75岁及以上服用DOAC的患者胃肠道出血事件随年龄增加而增多,风险在75岁人群中最髙。
研究设计与样本
- 回顾性、倾向匹配研究,使用OptumLabs数据仓库中私人保险个体和Medicare Advantage参保者的行政索赔数据。
- 构建三个倾向匹配队列:利伐沙班 vs 达比加群31,574例,阿哌沙班 vs 达比加群13,084例,阿哌沙班 vs 利伐沙班13,130例;入组时间为2010年10月1日至2015年2月28日。
- 采用按年龄分层的Cox比例风险模型估计总胃肠道出血率。
主要发现
- 利伐沙班组胃肠道出血发生率高于达比加群组(HR 1.20;95%CI 1.00-1.45)。
- 阿哌沙班组胃肠道出血风险低于达比加群组(HR 0.39;95%CI 0.27-0.58;P<.001)和利伐沙班组(HR 0.33;95%CI 0.22-0.49;P<.001)。
- 所有DOAC在75岁及以上患者中事件发生率均升高。
- 在非常高龄患者中,阿哌沙班与胃肠道出血相关的风险低于达比加群(HR 0.45;95%CI 0.29-0.71)和利伐沙班(HR 0.39;95%CI 0.25-0.61)。
- 胃肠道出血中位时间:阿哌沙班和利伐沙班<90天,达比加群<120天。
关键数值与推荐
- 利伐沙班 vs 达比加群:HR 1.20(95%CI 1.00-1.45)。
- 阿哌沙班 vs 达比加群:HR 0.39(95%CI 0.27-0.58;P<.001)。
- 阿哌沙班 vs 利伐沙班:HR 0.33(95%CI 0.22-0.49;P<.001)。
- 非常高龄患者中阿哌沙班 vs 达比加群:HR 0.45(95%CI 0.29-0.71)。
- 非常高龄患者中阿哌沙班 vs 利伐沙班:HR 0.39(95%CI 0.25-0.61)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Direct oral anticoagulant (DOAC) agents increase the risk of gastrointestinal (GI) bleeding. We investigated which DOAC had the most favorable GI safety profile and compared differences among these drugs in age-related risk of GI bleeding. METHODS: We conducted a retrospective, propensity-matched study using administrative claims data from the OptumLabs Data Warehouse of privately insured individuals and Medicare Advantage enrollees. We created 3 propensity-matched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran, rivaroxaban, or apixaban from October 1, 2010 through February 28, 2015. We compared data on rivaroxaban vs dabigatran for 31,574 patients, data on apixaban vs dabigatran for 13,084 patients, and data on apixaban vs rivaroxaban for 13,130 patients. Cox proportional hazards models, stratified by age, were used to estimate rates of total GI bleeding. RESULTS: Baseline characteristics were well balanced among sub-cohorts. GI bleeding occurred more frequently in patients given rivaroxaban than dabigatran (hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.00-1.45). Apixaban was associated with a lower risk of GI bleeding than dabigatran (HR, 0.39; 95% CI, 0.27-0.58; P < .001) or rivaroxaban (HR, 0.33; 95% CI, 0.22-0.49; P < .001). Rates of events for all DOACs increased among patients 75 years or older. Apixaban had a lower risk of association with GI bleeding in the very elderly than dabigatran (HR, 0.45; 95% CI, 0.29-0.71) or rivaroxaban (HR, 0.39; 95% CI, 0.25-0.61). Median times to GI bleeding were <90 days for apixaban and rivaroxaban and <120 days for dabigatran. CONCLUSIONS: In a population-based study of patients receiving DOAC agents, we found apixaban had the most favorable GI safety profile and rivaroxaban the least favorable profile. GI bleeding events among patient aged 75 years or older taking DOACs increased with age; the risk was greatest among persons 75 years. Apixaban had the most favorable GI safety profile among all age groups.
引用
- Abraham NS, Noseworthy PA, Yao X, et al. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology. 2016. PMID: 28043907. doi:10.1053/j.gastro.2016.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。